Colgate-Palmolive Company
NYSE:CLHousehold & Personal Products
-$0.71 today
- Market cap
- $78.58B
- Beta
- 0.32
- P/E (TTM)
- 34.5
- EPS (TTM)
- $2.60
- Dividend yield
- 2.33%
Volume 6.07M
Average 5.62M
CL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Colgate-Palmolive CompanyNYSE: CL
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development remains negative
Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0. Over 3 fiscal years it compounded at +4.6% a year.
Context
- Research & development amounted to 1.8% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 366M USD
- Year-over-year change
- +3.1%
- 4-year CAGR
- +4.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 366M | +3.1% |
| FY2024 | 2024-12-31 | 355M | +3.5% |
| FY2023 | 2023-12-31 | 343M | +7.2% |
| FY2022 | 2022-12-31 | 320M | +4.2% |
| FY2021 | 2021-12-31 | 307M | — |
Research & Development vs competitors
How CL compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -100.0% is the 2nd highest of 3, against a peer median of -50.4%.
- Research & development amounts to 0.0% of revenue for CL, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $180M USD | — | — | 1.2% | |
| LTM Sep 2026 | $117M USD | -0.8% | -5.6% | 1.6% | |
| LTM Sep 2026 | $0 USD | -100.0% | +4.6% | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| FY2025 | €0 EUR | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CL) | — | -50.4% | -5.6% | 0.0% | |
Competitors are the stored peer set for CL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.42B | 17.97B | 19.46B | 20.1B | 20.38B |
| Cost of Revenue | 7.13B | 7.82B | 8.21B | 8B | 8.13B |
| Gross Profit | 10.29B | 10.15B | 11.25B | 12.11B | 12.25B |
| Gross Margin | 59.1% | 56.5% | 57.8% | 60.2% | 60.1% |
| Research & Development | 307M | 320M | 343M | 355M | 366M |
| Selling, General & Admin | 6.1B | 6.25B | 6.78B | 7.81B | 7.89B |
| Operating Expenses | 6.41B | 6.57B | 7.12B | 7.72B | 8.95B |
| Depreciation & Amortization | 556M | 545M | 567M | 605M | 630M |
| EBITDA | 3.76B | 3.37B | 4.25B | 4.85B | 4.87B |
| EBITDA Margin | 21.6% | 18.8% | 21.8% | 24.1% | 23.9% |
| Operating Income | 3.89B | 3.59B | 4.13B | 4.38B | 3.31B |
| Operating Margin | 22.3% | 20.0% | 21.2% | 21.8% | 16.2% |
| Interest Income | 17M | 14M | 55M | 67M | 75M |
| Interest Expense | 117M | 167M | 287M | 292M | 267M |
| Other Income / Expenses | (799M) | (925M) | (739M) | (427M) | (247M) |
| Income Before Tax | 3.09B | 2.66B | 3.39B | 3.96B | 3.06B |
| Pre-Tax Margin | 17.7% | 14.8% | 17.4% | 19.7% | 15.0% |
| Income Tax Expense | 749M | 693M | 937M | 907M | 798M |
| Net Income | 2.17B | 1.79B | 2.3B | 2.89B | 2.13B |
| Net Margin | 12.4% | 9.9% | 11.8% | 14.4% | 10.5% |
| EPS (Basic) | 2.56 | 2.13 | 2.78 | 3.53 | 2.64 |
| EPS (Diluted) | 2.55 | 2.13 | 2.77 | 3.51 | 2.63 |
| Weighted Avg Shares | 845M | 836.4M | 827.4M | 817.7M | 808.7M |
| Weighted Avg Shares (Diluted) | 848.3M | 838.8M | 829.2M | 822.5M | 811.1M |
Colgate-Palmolive Company
NYSE:CL
Intrinsic Alpha fair value
Locked
Current Price
$98.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.